Antios
is a Georgia-based biopharmaceutical company that develops and commercializes therapies for the treatment of viral diseases... Read moreAntios
is a Georgia-based biopharmaceutical company that develops and commercializes therapies for the treatment of viral diseases... Read more
News
Jun 25, 2022
StreetInsider
Press Release: Antios : Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study
Jun 08, 2022
FirstWord Pharma
Antios: Antios Therapeutics Announces Oral Presentations on ATI-2173, ATI-1428, and ATI-1645 Hepatitis B Virus Programs at the EASL International Liver Congress 2022
May 25, 2022
FierceBiotechIT
Antios: Antios rocked as hepatitis B safety signal sparks clinical hold, termination of collaboration
May 25, 2022
Endpoints News
Antios: Antios' HBV collab axed after clinical hold, but biotech believes safety incident is not treatment-related
May 25, 2022
BioSpace
Antios: Clinical Hold on Antios' HBV Therapy Ends Deal with Assembly
Apr 26, 2022
Markets Insider
Antios: Antios Therapeutics Announces Notice of Allowance for U.S. Patent on Phosphoramidates for the Treatment of Hepatitis B Virus
Mar 30, 2022
FirstWord Pharma
Antios: Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies
Dec 15, 2021
FirstWord PHARMA
Antios: Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection
Dec 14, 2021
GlobeNewswire
Press Release: Antios : Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection
Dec 06, 2021
Markets Insider
Antios: Antios Therapeutics Announces Presentations on ATI-2173 at Hep DART 2021 Meeting
Antios Competitors
1
2
3
4
5